Q2 2026 13F · SEC CIK 1776382
venBio Partners LLC
Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $519.4M
- Reported positions
- 7
- Top holdings a year, 3 yrs
- +11.7%
- Average holding period
- 2.9 yrs
venBio Partners LLC is a hedge fund that reported 7 positions worth $519.4M in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Pharvaris N V (PHVS, 30.9%), Parabilis Medicines, Inc. (PBLS, 27.8%), Alumis Ord (ALMS, 24.5%). A portfolio copying its top holdings returned 11.7% a year over the last 3 years, against 20.4% for the S&P 500.
venBio Partners LLC holdings all 7 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| PHVSPharvaris N V | 30.9% | +0.1% | $160.6M |
| PBLSParabilis Medicines, Inc. | 27.8% | — | $144.1M |
| ALMSAlumis Ord | 24.5% | +0.0% | $127.4M |
| ACHVAchieve Life Science Inc | 7.4% | — | $38.6M |
| ALXOAlx Oncology Hldgs Inc | 5.1% | +0.0% | $26.7M |
| HRMYHarmony Biosciences Holdings I | 3.3% | -3.5% | $17.2M |
| LYELLyell Immunopharma Inc | 0.9% | +0.0% | $4.7M |
What venBio Partners LLC bought and sold in Q2 2026, against Q1 2026.
New positions
- PBLS Parabilis Medicines, Inc.27.8% of 13F
- ACHV Achieve Life Science Inc7.4% of 13F
Added to
No position grew by more than 5%.
Reduced
No position shrank by more than 5%.
Sold out
- ARTV Artiva Biotherapeutics Incwas 1.2%
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- +105.4% /yr
- S&P 500 +20.1%
- 3 years
- +11.7% /yr
- S&P 500 +20.4%
- 5 years
- -4.9% /yr
- S&P 500 +11.6%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $519.4M | 7 |
| Q1 2026 | $280.6M | 6 |
| Q4 2025 | $216.3M | 6 |
| Q3 2025 | $176.4M | 6 |
| Q2 2025 | $114.8M | 6 |
| Q1 2025 | $123.6M | 7 |
| Q4 2024 | $170.7M | 7 |
| Q3 2024 | $194.3M | 6 |
| Q2 2024 | $231.5M | 6 |
| Q1 2024 | $281.9M | 5 |
| Q4 2023 | $667.2M | 7 |
| Q3 2023 | $352.7M | 8 |
Questions about venBio Partners LLC's portfolio
What stocks does venBio Partners LLC own?
venBio Partners LLC's latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 7 positions worth $519.4M. The largest are Pharvaris N V (PHVS) at 30.9%, Parabilis Medicines, Inc. (PBLS) at 27.8%, Alumis Ord (ALMS) at 24.5%, Achieve Life Science Inc (ACHV) at 7.4% and Alx Oncology Hldgs Inc (ALXO) at 5.1%.
What did venBio Partners LLC buy last quarter?
In Q2 2026, venBio Partners LLC added a new position in Parabilis Medicines, Inc. (PBLS) and a new position in Achieve Life Science Inc (ACHV), compared with its Q1 2026 filing.
What did venBio Partners LLC sell last quarter?
In Q2 2026, venBio Partners LLC sold all of Artiva Biotherapeutics Inc (ARTV), compared with its Q1 2026 filing.
How has venBio Partners LLC's portfolio performed?
A portfolio copying venBio Partners LLC's 20 largest 13F holdings each quarter, from the day each filing was public, returned +11.7% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +105.4% against +20.1%. Over 5 years: -4.9% a year against +11.6%.
When is venBio Partners LLC's next 13F filing due?
13F filings are due 45 days after each quarter ends. venBio Partners LLC's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.